PBM Psyence Biomedical Ltd.
USHealthcareAs of 2026-08-24
Why PBM matters now
Psyence Biomedical Ltd. (PBM) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.22 with -2.54% on the session and $80.3K in market capitalization; recent performance reads 1-month -19.44% and YTD -33.26%.
The latest financial table shown here is Q2 2025, with revenue of $0.00, net income of $-753.3K, and EPS of $-0.51. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6249.6%.
The latest indexable market news headline is "Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development" from GlobeNewsWire.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.27
P/S
0.00
EV/EBITDA
-5.93
DCF Value
$7.58
FCF Yield
-6249.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.6%
ROA
13.8%
ROIC
-54.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0.00 | $-753.3K | $-0.51 |
| FY 2024 | $0.00 | $1.0M | $1.78 |
| Q2 2024 | $0.00 | $141.5K | $4.06 |
| FY 2023 | $0.00 | $-51.2M | $-7.85 |
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.65
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.